What are the treatment options for emphysema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Emphysema treatment should prioritize a combination of medications, lifestyle changes, and pulmonary rehabilitation to manage symptoms and slow disease progression, as recommended by the most recent guidelines 1. The primary goal of emphysema treatment is to improve quality of life, reduce symptoms, and slow disease progression. According to the European Respiratory Journal study from 2016 1, treatment options vary depending on the patient's condition and risk of exacerbations.

Key Treatment Options:

  • Bronchodilators like tiotropium (Spiriva, 18 mcg once daily) or salmeterol (Serevent, 50 mcg twice daily) to open airways
  • Inhaled corticosteroids like fluticasone (100-500 mcg twice daily) to reduce inflammation, often combined with long-acting bronchodilators
  • Roflumilast (Daliresp, 500 mcg daily) to reduce exacerbations in severe cases
  • Oxygen therapy when blood oxygen levels fall below 88%, typically starting at 2-3 liters per minute
  • Pulmonary rehabilitation programs combining exercise, education, and support
  • Smoking cessation to prevent further lung damage
  • Surgical options like lung volume reduction surgery, bullectomy, or lung transplantation in advanced cases These treatments aim to reduce airway obstruction, decrease inflammation, and improve oxygen exchange in the lungs, ultimately managing breathlessness and improving quality of life despite the permanent nature of emphysema's lung damage, as noted in the European Respiratory Society task force study from 1995 1.

Patient-Specific Treatment:

Treatment should be tailored to the individual patient's needs, taking into account their symptoms, risk of exacerbations, and overall health status. The 2016 study 1 provides guidance on treatment options for different patient types, including those with bronchitis, emphysema, and frequent exacerbations.

Importance of Pulmonary Rehabilitation:

Pulmonary rehabilitation programs are essential in emphysema treatment, as they combine exercise, education, and support to improve patients' quality of life and reduce symptoms. These programs should be individualized to meet each patient's needs and goals.

Conclusion is not allowed, so the answer just ends here with the last relevant information.

From the FDA Drug Label

STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema The treatment option for emphysema is STIOLTO RESPIMAT, a combination of tiotropium bromide and olodaterol, used for long-term, once-daily maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema 2.

  • The recommended dosage of STIOLTO RESPIMAT is two inhalations once-daily at the same time of the day.
  • STIOLTO RESPIMAT is not indicated to treat acute deteriorations of COPD or asthma.

From the Research

Emphysema Treatment Options

Emphysema is a type of chronic obstructive pulmonary disease (COPD) that requires comprehensive management. The treatment options for emphysema include:

  • Medications: bronchodilators, such as tiotropium, to help relax airway muscles and improve breathing 3, 4
  • Combination therapies: using multiple medications, such as salmeterol/fluticasone and tiotropium, to control symptoms and improve lung function 5
  • Lifestyle changes: quitting smoking, avoiding air pollutants, and staying physically active to slow disease progression

Medication Therapies

Medications play a crucial role in managing emphysema symptoms. Some key findings include:

  • Tiotropium has been shown to be effective in preventing exacerbations and improving lung function in patients with moderate-to-very-severe COPD 3, 4
  • Long-acting bronchodilators, such as tiotropium, can be used as first-line therapy for patients with symptomatic COPD 6
  • Combination therapies, such as salmeterol/fluticasone and tiotropium, may provide better control of symptoms and improved lung function compared to single therapies 5

Treatment Goals

The primary goals of emphysema treatment are to:

  • Improve symptoms and quality of life
  • Slow disease progression
  • Prevent exacerbations and hospitalizations
  • Enhance lung function and overall health status 3, 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2008

Research

Pharmacology and therapeutics of bronchodilators.

Pharmacological reviews, 2012

Related Questions

Is dead space in the lungs referring to oxygen that isn't participating in gas exchange or any air, including carbon dioxide (CO2), that isn't participating in gas exchange, particularly in conditions like Chronic Obstructive Pulmonary Disease (COPD)?
What are the benefits of Ohtuvayre (not a recognized medication, possibly referring to a medication for COPD) in Chronic Obstructive Pulmonary Disease (COPD)?
What are the treatment options for Chronic Obstructive Pulmonary Disease (COPD) exacerbation?
Does chronic obstructive pulmonary disease (COPD) lead to airflow obstruction, resulting in air trapping, hyperinflation of the lung, increased volume (V) with unchanged flow (Q), and ultimately increased dead space?
What is the diagnosis for a 73-year-old patient presenting with a 5-month history of cough, where the chest X-ray (CXR) shows no acute cardiopulmonary abnormality, but findings suggest chronic small airways disease and mild pulmonary fibrosis?
What is the classification of heart failure according to functional capacity and symptoms, specifically the New York Heart Association (NYHA) classification?
How do you classify and treat heart failure based on left ventricular ejection fraction (LVEF)?
Which lung nodules require follow-up computed tomography (CT) scans?
What are the recommendations for managing drug-induced hemolysis in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
What medications should be avoided in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.